ranolazine + dronedarone

**ranolazine + dronedarone** is a combination of two antiarrhythmic small molecules used together to treat atrial fibrillation (AF). Ranolazine acts by selectively inhibiting the late sodium current (INa) in cardiac cells, leading to atrial-selective depression of sodium channel–dependent parameters including the maximal rate of rise of the action potential upstroke and the development of post-repolarization refractoriness. Dronedarone is a noniodinated derivative of amiodarone that blocks multiple cardiac ion channels including sodium, potassium, and calcium channels, as well as adrenergic receptors. When combined, ranolazine and dronedarone exert a potent synergistic effect, causing significant atrial-selective depression of sodium channel–dependent parameters and effective suppression and prevention of AF. This combination has been shown in preclinical and clinical studies to provide greater reduction in AF burden than either drug alone, with improved safety and tolerability at reduced individual doses[1][2][3][4].

Other names

ranolazine + dronedarone